The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases

Cellular and Molecular Immunology

Volumn 12, Issue 5, 2015, Pages 533-542

  Park, Benjamin V ^a   Pan, Fan ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 3 [(4 ANILINO 2 METHOXYPHENYL)SULFAMOYL] 2 THENOIC ACID METHYL ESTER; AROMATIC HYDROCARBON RECEPTOR; CELL NUCLEUS RECEPTOR; CH 233191; DIGOXIN; GSK 2033; GSK 3787; GW 6471; IMMUNOMODULATING AGENT; LE 135; LE 540; LIVER X RECEPTOR; NUCLEAR RECEPTOR NUR77; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA T; RO 41 5253; SR 1001; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CELL RECEPTOR;

CD4+ T LYMPHOCYTE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE CONTROL; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LIGAND BINDING; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN FUNCTION; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; BIOLOGICAL MODEL; DISEASES; IMMUNOLOGY; METABOLISM;

DISEASE; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84941129470     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.21     Document Type: Review

References (110)

1. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2: 933-944.
2. Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000; 192: 1545-1552.
3. Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends Immunol 2014; 35: 61-68.
4. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-350.
5. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
6. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. 2006 Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24: 677-688.
7. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-171 T helper cells. Cell 2006; 126: 1121-1133.
8. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008; 10: 206.
9. Han L, Yang J, Wang X, Li D, Lv L, Li, B. Th17 cells in autoimmune diseases. Front Med 2015; 9: 10-19.
10. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008; 28: 29-39.
11. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179: 4313-4317.
12. Villarino AV, Gallo E, Abbas AK. STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J Immunol 2010; 185: 6461-6471.
13. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26: 371-381.
14. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell; 146: 772-784.
15. DCruz LM, Klein L. Development and function of agonist-induced CD251Foxp31 regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6: 1152-1159.
16. Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev 2011; 241: 260-268.
17. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp31 regulatory T cells: more of the same or a division of labor? Immunity 2009; 30: 626-635.
18. Shevach EM. Mechanisms of Foxp31 T regulatory cell-mediated suppression. Immunity 2009; 30: 636-645.
19. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B et al. Retinoic acid increases Foxp31 regulatory T cells and inhibits development of Th17 cells by enhancing TGF-b-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008; 181: 2277-2284.
20. BurchillMA,Yang J,VogtenhuberC,Blazar BR, FarrarMA.IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp31 regulatory T cells. J Immunol 2007; 178: 280-290.
21. van Loosdregt J, Fleskens V, Fu J, Brenkman AB, Bekker CP, Pals CE et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 2013; 39: 259-271.
22. Chen Z, Barbi J, Bu S, Yang HY, Li Z, Gao Y et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 2013; 39: 272-285.
23. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD et al. TGFbeta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453: 236-240.
24. Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, NakayaM et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem 2008; 283: 17003-17008.
25. Heller JJ, Qiu J, Zhou L. Nuclear receptors take center stage in Th17 cell-mediated autoimmunity. J Clin Invest 2011; 121: 519-521.
26. Klotz L, Knolle P. Nuclear receptors: TH17 cell control from within. FEBS Lett 2011; 585: 3764-3769.
27. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839.
28. Khan S, Lingrel JB. Thematic minireview series on nuclear receptors in biology and diseases. J Biol Chem 2010; 285: 38741-38742.
29. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748-759.
30. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-850.
31. Schupp M, Lazar MA. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem 2010; 285: 40409-40415.
32. RosenfeldMG, GlassCK. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem2001; 276: 36865-36868.
33. Jetten AM, Kurebayashi S, Ueda E. TheRORnuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol 2001; 69: 205-247.
34. Manel N, Unutmaz D, LittmanDR The differentiation of human T(H)-cells requires transforming growth factor-b and induction of the nuclear receptor RORcT. Nat Immunol 2008; 9: 641-649.
35. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M et al. IL-21 and TGF-[bgr] are required for differentiation of human TH17 cells. Nature 2008; 454: 350-352.
36. Huh JR, Leung MWL, Huang P, Ryan DA, Krout MR, Malapaka RRV et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR[ggr]t activity. Nature 2011; 472: 486-490.
37. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011; 472: 491-494.
38. Burgler S, Mantel PY, Bassin C, Ouaked N, Akdis CA, Schmidt-Weber CB RORC2 is involved in T cell polarization through interaction with the FOXP3 promoter. J Immunol 2010; 184: 6161-6169.
39. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 44-56.
40. Gianni M, Li Calzi M, Terao M, Guiso G, Caccia S, Barbui T et al. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood 1996; 87: 1520-1531.
41. Chambon P. A decade of molecular biology of retinoic acid receptors. Faseb J 1996; 10: 940-954.
42. Zhou X, Kong N, Wang J, Fan H, Zou H, Horwitz D et al. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol 2010; 185: 2675-2679.
43. Golovina TN, Mikheeva T, Brusko TM, Blazar BR, Bluestone JA, Riley JL. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE 2011; 6: e15868.
44. Takeuchi H, Yokota-Nakatsuma A, Ohoka Y, Kagechika H, Kato C, Song SY et al. Retinoid X receptor agonists modulate Foxp3(1) regulatory T cell and Th17 cell differentiation with differential dependence on retinoic acid receptor activation. J Immunol 2013; 191: 3725-3733.
45. Mucida D, Pino-Lagos K, Kim G, Nowak E, Benson MJ, Kronenberg Met al. Retinoic acid can directly promote TGF-b-mediated Foxp31 Treg cell conversion of naive T cells. Immunity 2013; 30: 471-472.
46. Nolting J, Daniel C, Reuter S, Stuelten C, Li P, Sucov H et al. Retinoic acid can enhance conversion of naive into regulatory T cells independently of secreted cytokines. J Exp Med 2009; 206: 2131-2139.
47. Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, Chambon P et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD41CD44hi cells. Immunity 2008; 29: 758-770.
48. Schambach F, Schupp M, Lazar MA, Reiner SL. Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol 2007; 37: 2396-2399.
49. Bai A, Lu N, Guo Y, Liu Z, Chen J, Peng Z. All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J Leukoc Biol 2009; 86: 959-969.
50. Jafarirad S, Siassi F, Harirchian MH, Sahraian MA, Eshraghian MR, Shokri F et al. The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. J Neurosci Rural Pract 2012; 3: 294-298.
51. Harrirchian MH, Mohammadzadeh Honarvar N, Koohdani F, Bitarafan S, Siassi F, Jafarirad S et al. The effect of vitamin a supplementation on disease progression, cytokine levels and gene expression in multiple sclerotic patients: study protocol for a randomized controlled trial. Acta Medica Iranica 2014; 52: 94-100.
52. Fragoso YD, Stoney PN, McCaffery PJ. The evidence for a beneficial role of vitamin A in multiple sclerosis. CNS Drugs 2014; 28: 291-299.
53. Gebel T, Arand M, Oesch F. Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. FEBS Lett 1992; 309: 37-40.
54. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell 1993; 77: 67-76.
55. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012; 486: 549-553.
56. Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S et al. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 2009; 206: 2079-2089.
57. Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol 2009; 182: 7625-7633.
58. Wang LH, Yang XY, Zhang X, Huang J, Hou J, Li J et al. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity 2004; 20: 205-218.
59. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 2007; 178: 4129-4135.
60. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD41 T cell-mediated protection against colitis. J Immunol 2007; 178: 2940-2949.
61. Kanakasabai S, Walline CC, Chakraborty S, Bright JJ. PPARdelta deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis. Brain Res 2011; 1376: 101-112.
62. Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S et al. Peroxisome proliferator-activated receptor (PPAR)a expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med 2007; 204: 321-330.
63. Zhang MA, Rego D, Moshkova M, Kebir H, Chruscinski A, Nguyen H et al. Peroxisome proliferator-activated receptor (PPAR)a and -c regulate IFNc and IL-17A production by human T cells in a sexspecific way. Proc Nat Acad Sci 2012; 109: 9505-9510.
64. Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH et al. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol 2009; 182: 4479-4487.
65. Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ. Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 2010; 130: 572-588.
66. Lei J, Hasegawa H, Matsumoto T, Yasukawa M. Peroxisome proliferator-activated receptor alpha and gamma agonists together with TGF-beta convert human CD41CD25-T cells into functional Foxp31 regulatory T cells. J Immunol 2010; 185: 7186-7198.
67. Dubrac S, Elentner A, Schoonjans K, Auwerx J, Schmuth M. Lack of IL-2 in PPAR-alpha-deficient mice triggers allergic contact dermatitis by affecting regulatory T cells. Eur J Immunol 2011; 41: 1980-1991.
68. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM et al. Oxidative metabolism of linoleic acid modulates PPAR-beta//delta suppression of PPAR-gamma activity. Oncogene 2005; 25: 1225-1241.
69. Pershadsingh HA, Heneka MT, Saini R, Amin NM, Broeske DJ, Feinstein DL. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 2004; 1: 3.
70. Hack K, Reilly L, Palmer C, Read KD, Norval S, Kime R et al. Skintargeted inhibition of PPAR b/d by selective antagonists to treat PPAR b/d -mediated psoriasis-like skin disease in vivo. PLoS ONE 2012; 7: e37097.
71. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008; 21: 102-116.
72. Poland A, Glover E, Kende AS. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J Biol Chem 1976; 251: 4936-4946.
73. Rannug A, Rannug U, Rosenkranz HS, Winqvist L, Westerholm R, Agurell E et al. Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances. J Biol Chem 1987; 262: 15422-15427.
74. Oberg M, Bergander L, Hakansson H, Rannug U, Rannug A. Identification of the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole, in cell culture medium, as a factor that controls the background aryl hydrocarbon receptor activity. Toxicol Sci 2005; 85: 935-943.
75. Yasui T, Kim EY, Iwata H, Franks DG, Karchner SI, Hahn ME et al. Functional characterization and evolutionary history of two aryl hydrocarbon receptor isoforms (AhR1 and AhR2) from avian species. Toxicol Sci 2007; 99: 101-117.
76. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC et al. The aryl hydrocarbon receptor links TH17-cellmediated autoimmunity to environmental toxins. Nature 2008; 453: 106-109.
77. Veldhoen M, Hirota K, Christensen J, OGarra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009; 206: 43-49.
78. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Nat Acad Sci 2008; 105: 9721-9726.
79. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008; 453: 65-71.
80. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(1) regulatory T cells. Nat Immunol 2010; 11: 846-853.
81. Pot C. Aryl hydrocarbon receptor controls regulatory CD41 T cell function. Swiss Med Wkly 2012; 142: w13592.
82. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA 2010;107: 19961-19966.
83. Quintana FJ, Murugaiyan G, Farez MF, Mitsdoerffer M, Tukpah AM, Burns EJ et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010; 107: 20768-20773.
84. Maxwell MA, Muscat GE. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal 2006; 4: e002.
85. Kurakula K, Koenis DS, van Tiel CM, de Vries CJ. NR4A nuclear receptors are orphans but not lonesome. Biochim Biophys Acta 2014; 1843(11): 2543-2555.
86. Fassett MS, Jiang W, DAlise AM, Mathis D, Benoist C. Nuclear receptor Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion. Proc Natl Acad Sci USA 2012; 109: 3891-3896.
87. Raveney BJE, Oki S, Yamamura T. Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling. PLoS ONE 2013; 8: e56595.
88. Sekiya T, Kashiwagi I, Inoue N, Morita R, Hori S, Waldmann H et al. The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD41 T cells. Nat Commun 2011; 2: 269.
89. Sekiya T, Kashiwagi I, Yoshida R, Fukaya T, Morita R, Kimura A et al. Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. Nat Immunol 2013; 14: 230-237.
90. Kang SW, Kim SH, Lee N, Lee WW, Hwang KA, Shin MS et al. 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. J Immunol 2012; 188: 5276-5282.
91. Khoo AL, Joosten I, Michels M, Woestenenk R, Preijers F, He XH et al. 1,25-Dihydroxyvitamin D3 inhibits proliferation but not the suppressive function of regulatory T cells in the absence of antigen-presenting cells. Immunology 2011; 134: 459-468.
92. Bruce D, Yu S, Ooi JH, Cantorna MT. Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling. Int Immunol 2011; 23: 519-528.
93. Smolders J, Thewissen M, Peelen E, Menheere P, Cohen Tervaert JW, Damoiseaux J et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS ONE 2009; 4: e6635.
94. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JPA. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014; 348: g2035.
95. Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT. Therapeutic effect of vitamin d supplementation in a pilot study of Crohns patients. Clin Transl Gastroenterol 2013; 4: e33.
96. OSullivan, M. Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn? Proc Nutr Soc 2015; 74: 5-12.
97. Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. J Endocrinol 2010; 204: 233-240.
98. Bensinger SJ, BradleyMN, Joseph SB, Zelcer N, Janssen EM, Hausner MAet al. LXR signaling couples sterolmetabolismto proliferation in the acquired immune response. Cell 2008; 134: 97-111.
99. Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest 2011; 121: 658-670.
100. Vucic E, Calcagno C, Dickson SD, Rudd JH, Hayashi K, Bucerius J et al. Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC Cardiovasc Imaging 2012; 5: 819-828.
101. Sodhi RK, Singh N. Liver X receptors: emerging therapeutic targets for Alzheimers disease. Pharmacol Res 2013; 72: 45-51.
102. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol 2012; 13: 907-915.
103. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD41T cell subsets. J Immunol 2011; 186: 3299-3303.
104. Michalek RD, Gerriets VA, Nichols AG, Inoue M, Kazmin D, Chang CY et al. Estrogen-related receptor-alpha is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci USA 2011; 108: 18348-18353.
105. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33: 301-311.
106. Barbi J, Pardoll D, Pan F. Metabolic control of the Treg/Th17 axis. Immunol Rev 2013; 252: 52-77.
107. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008; 58: 875-887.
108. Jamshidian A, Shaygannejad V, Pourazar A, Zarkesh-Esfahani SH, Gharagozloo M. Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. J Neuroimmunol 2013; 262: 106-112.
109. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127: 759-767.
110. Kaipainen A, Kieran MW, Huang S, Butterfield C, Bielenberg D, Mostoslavsky G et al. PPARa deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2007; 2: e260.